May 302013
A Fundamental Take On Alkermes’ Turnaround Story
Seeking Alpha
These products are for multiple sclerosis complication, Opioid dependence, alcohol dependence, schizophrenia and Type 2 diabetes. The drugs are in the early phase of the product cycle, and hence the possibility of faster growth in revenues is …http://seekingalpha.com/article/1467401-a-fundamental-take-on-alkermes-turnaround-story?source=google_news
The product pipeline consists of drugs like ZOHYDRO ER (pain) for which patent has been filed, and other drug candidates like Exenatide (Type 2 diabetes), Aripiprazole Lauroxil (schizophrenia), INVEGA SUSTENNA (schizophrenia), ALKS 5461 (major depressive disorder), and ALKS 3831 (schizophrenia), which are in phase 2/phase 3 of trial.
Sorry, the comment form is closed at this time.